Oligo/amenorrhea

Testing for PCOS

Management of PCOS

Conclusion

References

PCOS and Reproductive Health

Insulin resistance with compensatory hyperinsulinemia affects ~65–70% of women with PCOS (10). An estimated 30–40% of PCOS patients have impaired glucose tolerance (IGT), and 7.5–10% have type 2 diabetes (7,9). Conversely, the prevalence of PCOS is elevated among women who have already been diagnosed with type 1 or type 2 diabetes (2). Studies suggest that the annual progression rate from normal glucose tolerance to IGT and from IGT to type 2 diabetes in women is substantially enhanced among women with PCOS, with the highest risk in women who are also obese and have a family history of type 2 diabetes (9,11). A 2010 systematic review and meta-analysis (12) of 35 studies found that PCOS is associated with a 2.5-fold increased prevalence of IGT and a fourfold increased prevalence of type 2 diabetes. Insulin resistance, which occurs independently of obesity in PCOS (2), may affect ovulation and fertility by interfering with hepatic production of sex hormone–binding globulin.
(SHBG) (13). Reduced SHBG levels lead to an increase in free testosterone levels (14). Women with PCOS who have chronic anovulation but normal androgen levels tend to not be insulin resistant (15). The combination of anovulation and hyperinsulinemia can promote endometrial cell proliferation, increasing the risk of endometrial carcinomas and other abnormalities (16).

In addition to glucose and insulin abnormalities, CVD risk factors (hypertension, hyperlipidemia, impaired blood vessel function) often accompany PCOS (1,2). In the United States, 33–47% of women with PCOS have metabolic syndrome, a rate two to three times higher than that of age-matched healthy women without PCOS (16). Women with PCOS also have a four- to sevenfold higher risk of having a heart attack than women of the same age who do not have PCOS (17). Between 35 and 60% of women with PCOS are obese (15), which appears to worsen both the metabolic and reproductive features of the condition, particularly in cases of visceral adiposity (18). PCOS and metabolic syndrome have many anthropometric and metabolic abnormalities in common, and hyperinsulinemia may be a crucial link between the two conditions (14). Women who have PCOS and metabolic syndrome or type 2 diabetes are at the highest risk of CVD (19). Production of androgens tends to decrease in the years leading to menopause, so the menstrual cycles of women with PCOS often become more regular, with corresponding improvement in reproductive functioning (20,21). However, research on the impact of PCOS on cardiovascular risk in the postmenopausal years is inconclusive and lacking (22,23).

**Etiology of PCOS**

Although the exact cause of PCOS is unknown, it is understood to be a multifactorial condition with a genetic component. Approximately 20–40% of first-degree female relatives of women with PCOS go on to develop PCOS themselves, compared to an estimated 4–6% prevalence in the general population (16). Many women with PCOS have female relatives with PCOS, even if it was never diagnosed (2). As with type 2 diabetes, it is likely that numerous genes each make a small contribution to the etiology of PCOS; and recent genome-wide association studies have identified candidate genes (2,3,16). Any underlying genetic predisposition is likely complicated by epigenetic and environmental factors such as an unhealthy diet and lack of physical activity (3,16).

**Diagnosing PCOS**

Diagnosing and treating PCOS is important to preserve or restore fertility, reduce symptoms, and prevent complications that can develop in women with PCOS from adolescence to the postmenopausal period. Obstacles to timely diagnosis include the presence of multiple PCOS phenotypes and significant individual variation in clinical features, as well as competing diagnostic criteria from the National Institutes of Health (NIH), the European Society for Human Reproduction and Embryology and American Society for Reproductive Medicine (ESHRE/ASRM Rotterdam), and the Androgen Excess and PCOS Society (AE-PCOS) (Table 1) (3,15). To be diagnosed with PCOS under the ESHRE/ASRM Rotterdam criteria, which are considered to be a compromise between those of NIH and AE-PCOS, a woman must have at least two of three criteria after other related health conditions are ruled out: oligo-ovulation and/or anovulation, clinical and/or biochemical signs of hyperandrogenism, and polycystic ovaries visible by ultrasound (24,25). Although approximately three out of four women with PCOS have polycysts on their ovaries, this clinical feature is no longer deemed necessary or sufficient for diagnosis. One recommendation from the NIH Evidence-Based Methodology Workshop on Polycystic Ovary Syndrome held in December 2012 was that PCOS be renamed to more accurately reflect the complex nature of this syndrome and its implications for women’s reproductive and metabolic health (3).

Clinically, PCOS may manifest as a mild menstrual disorder or a severe disturbance of reproductive and metabolic functions (15). Most visible signs are caused by excessive production of insulin or androgens. Hirsutism (excess hair growth on the face and body) is present in ~ 70% of women with PCOS and is considered to be a good marker for hyperandrogenism, and alopecia (thinning scalp hair), acne, and other skin symptoms are less common and are not good markers (20). Oral contra-

<table>
<thead>
<tr>
<th>TABLE 1. Diagnostic Criteria for PCOS</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIH, 1990</td>
</tr>
<tr>
<td>Both criteria needed:</td>
</tr>
<tr>
<td>• Chronic anovulation</td>
</tr>
<tr>
<td>• Clinical and/or biochemical signs</td>
</tr>
<tr>
<td>of hyperandrogenism (with exclu-</td>
</tr>
<tr>
<td>sion of other etiologies)</td>
</tr>
<tr>
<td>ESHRE/ASRM</td>
</tr>
<tr>
<td>Rotterdam, 2003</td>
</tr>
<tr>
<td>Two of three criteria needed:</td>
</tr>
<tr>
<td>• Oligo-ovulation and/or anovulation</td>
</tr>
<tr>
<td>• Clinical and/or biochemical signs</td>
</tr>
<tr>
<td>of hyperandrogenism</td>
</tr>
<tr>
<td>• Polycystic ovaries</td>
</tr>
<tr>
<td>AE-PCOS Society, 2006</td>
</tr>
<tr>
<td>Both criteria needed:</td>
</tr>
<tr>
<td>• Clinical and/or biochemical signs</td>
</tr>
<tr>
<td>of hyperandrogenism</td>
</tr>
<tr>
<td>• Ovarian dysfunction (oligo-</td>
</tr>
<tr>
<td>anovulation and/or polycystic</td>
</tr>
<tr>
<td>ovaries)</td>
</tr>
</tbody>
</table>
Reproductive and Metabolic Complications in Women with PCOS

PCOS is a condition that affects roughly 10% of women of reproductive age and is characterized by anovulation, hyperandrogenism, and polycystic ovaries. This condition can lead to a range of reproductive and metabolic complications, including menstrual irregularities, polycystic ovaries, and metabolic syndrome, which can increase the risk of developing type 2 diabetes and cardiovascular disease.

**Symptoms of Hyperandrogenism and Metabolic Complications**

The symptoms of hyperandrogenism and metabolic complications in women with PCOS can be significant and include:

- **Menstrual irregularities**: Irregular or absent menstrual cycles.
- **Polycystic ovaries**: Presence of multiple small follicles in the ovaries on ultrasound.
- **Obesity**: Increased body weight and fat distribution.
- **Metabolic syndrome**: Presence of multiple metabolic risk factors such as high blood pressure, high triglycerides, low HDL cholesterol, and high fasting glucose.
- **Diabetes**: Increased risk of developing type 2 diabetes.
- **Cardiovascular disease**: Increased risk of developing cardiovascular disease.

These symptoms can be managed through lifestyle interventions and, in some cases, medical treatments.

**Lifestyle Interventions**

Lifestyle interventions, such as diet and exercise, can help to improve the symptoms of PCOS and reduce the risk of developing metabolic and reproductive complications. Dietary interventions, such as a low-glycemic diet, can help to improve insulin sensitivity and reduce circulating insulin and androgen levels. Exercise can also help to improve insulin sensitivity and reduce body weight.

**Medical Nutrition Therapy (MNT)**

Medical nutrition therapy (MNT) is a key component of the treatment plan for women with PCOS. MNT can help to improve clinical outcomes and reduce the risk of developing metabolic and reproductive complications. MNT can help to improve insulin sensitivity, reduce circulating insulin and androgen levels, and improve lipid and FSH levels.

**NUTRITION FYI**

Treating PCOS: Lifestyle Interventions

Because the underlying pathophysiology of PCOS has not been fully determined yet, treatment plans typically focus on specific symptoms. Lifestyle change (dietary, exercise, or behavioral interventions) is considered the first-line treatment for management of infertility and metabolic complications in women with PCOS, including reduction of the conversion rate from IGT to type 2 diabetes (2,9,28) and CVD risk (19).

Intensive lifestyle modification and weight reduction has been shown to reduce circulating insulin and androgen levels and improve lipid and FSH levels, which can reduce many of the physical symptoms, normalize menstrual cycles, induce ovulation, and improve general health (1,8,15,16).

For women with PCOS who are overweight or obese, weight loss of as little as 5–10% has been associated with significant clinical benefits in improving reproductive, metabolic, and psychological features of the condition (2,7).

No specific dietary composition has been demonstrated to be most beneficial, in part because of clinical heterogeneity and methodological problems with the current body of research (29,30). A recent systematic review (30) found that subtle but inconclusive improvements were observed with a low-glycemic diet but that further research is needed. This review did find that a nutritionally adequate weight loss diet based on healthy food choices was of clinical benefit in overweight and obese women with PCOS regardless of the diet composition.

Along with a healthful eating plan, regular physical activity can help with many of the issues and health concerns that surround PCOS by increasing SHBG and decreasing androgen levels, improving insulin sensitivity, assisting with weight management, improving lipid levels, and lowering blood pressure (31). Regular physical activity can also improve mood and body image and help reduce chronic stress and stress-related eating, although women with PCOS should also be screened for mood and anxiety disorders and treated using established therapies (6). Vitamin D deficiency is common in women with PCOS, and there is limited evidence that vitamin D supplementation may improve reproductive function and insulin sensitivity (32). Although more randomized controlled trials are needed, vitamin D levels should be tested, and supplementation may be warranted to increase low levels, especially in women undergoing in vitro fertilization (33).

Medical nutrition therapy (MNT) can help women with PCOS make and maintain the lifestyle changes needed to help reduce symptoms and prevent complications. MNT is based on an assessment of lifestyle changes that would help a patient with PCOS achieve and maintain clinical goals. The Academy of Nutrition and Dietetics’ evidence-based nutrition practice guidelines (34) recommend the following structure for the implementation of MNT for adults with PCOS:

- **Thorough nutrition assessment to help prioritize MNT**
- **Nutrition diagnosis, which includes the presence of, risk of, or potential for developing a nutritional deficit that can be addressed by nutrition therapy**
- **Nutrition interventions, which are specific actions to remed[y the nutrition diagnosis; these can include clinical and behavioral goals collaboratively agreed upon with the patient, as well as specific nutrition interventions such as selecting a meal-planning strategy or education on controlling...**
to improved health outcomes.

The following case study demonstrates how MNT can effectively facilitate lifestyle changes that lead to improved health outcomes.

Case Study: MNT in PCOS

Patient
The patient, Gita, is a 27-year-old South-Asian female referred for MNT with diagnoses of PCOS and infertility.

Food- and Nutrition-Related History
Gita is a lacto-vegetarian who consumes no eggs because of her religious beliefs. She typically skips breakfast; eats a granola bar or orange juice for lunch; snacks on chocolate candy bars, juice, or fruit smoothies; and then enjoys a full supper of vegetarian curry, basmati rice, vegetables, and lentils. She reports having gained 20 lb since moving to the United States from India 1 year ago.

Nutrient Intake
• Most calories consumed at night
• Diet high in carbohydrates

Activity
• Very minimal physical activity

Anthropometrics
• Height: 5 feet, 3 inches
• Weight: 162 lb
• BMI: 28.7 kg/m²
• Waist circumference: 38.4 inches

Biochemical Data
• A1C: 5.5% (normal 4.5–6%) (1)
• Fasting blood glucose: 90 mg/dL (normal 70–100 mg/dL)
• Vitamin D: 6 ng/mL (normal 30.0–74.0 ng/mL)
• Cholesterol: 188 mg/dL (normal <200 mg/dL)
• HDL cholesterol: 34 mg/dL (normal ≥60 mg/dL)

Nutrition Diagnoses
• Diagnosis 1: Excessive carbohydrate intake related to knowledge deficit as evidenced by diet history and BMI
• Diagnosis 2: Physical inactivity related to knowledge deficit as evidenced by current physical activity level

Nutrition Intervention
Gita agreed to eat three meals and two snacks daily, distributing carbohydrates with fat and protein throughout the day. She can now identify the carbohydrate content of Indian dishes and knows how to balance carbohydrate portions. She understands how to add protein sources to meals and snacks by adding servings of soy milk and yogurt and by using lentils, beans, edamame, and quinoa to provide protein and low-glycemic carbohydrates. She will increase her intake of omega-3 fatty acids through food sources such as nuts, flax, and chia seeds. She also agreed to include the following supplements in her routine: vitamin D (50,000 IU weekly for 8 weeks), ground flax, and a prenatal multivitamin and mineral. In terms of physical activity, she will begin with 15 minutes of walking daily and gradually work up to 45 minutes daily.

Monitoring/Evaluation
• Record dietary intake, including carbohydrate servings, and e-mail them directly to the registered dietitian every week
• Meet for in-person MNT sessions every 3–4 weeks

Outcomes
Gita lost 12 lb (8% of baseline body weight) over 6 months and successfully conceived a healthy son through the use of timed intercourse. She met with the dietitian for an additional nutrition session during pregnancy, and her glucose tolerance test result was normal.

Treating PCOS: Pharmaceutical Interventions
When lifestyle treatment does not result in desired outcomes, pharmacotherapy may be added. In premenopausal patients not currently trying to become pregnant, the Endocrine Society recommends hormonal contraceptives as the first-line therapy to manage menstrual abnormalities and reduce hirsutism and acne (2,35). Metformin helps to improve insulin sensitivity in both women and adolescents with PCOS, which in turn can decrease circulating androgen levels and normalize the menstrual cycle and ovulation (2,15,36). Clomiphene citrate, an estrogen receptor antagonist, is the drug of first choice for induction of ovulation in women with PCOS (2). However, most published, randomized, controlled trials that used medications such as clomiphene citrate or metformin failed to find significant differences in menstrual function between lifestyle intervention and pharmacotherapy. For that reason, in infertile overweight or obese adults with PCOS, evidence does not support treatment with these drugs ahead of either lifestyle intervention alone or starting lifestyle treatment in combination with these drugs (29,37,38). The Endocrine Society recommends metformin for adult PCOS patients with IGT or type 2 diabetes when lifestyle interventions alone are not sufficient and for adolescent patients who have IGT or metabolic syndrome (35).

Summary
Although PCOS is treatable with lifestyle changes and medication, many of the estimated 1 in 10 women with this condition go without adequate treatment because of underdiagnosis. To facilitate accurate diagnosis and timely treatment, clinicians who see female patients need to be familiar with the diversity of PCOS phenotypes that may be encountered in a clinical setting. The adverse effects of PCOS on ovulation and fertility understandably garner much attention, but this condition has broader implications for a woman’s metabolic and...
psychological health before, during, and after her reproductive years, and treatment interventions should reflect that fact.

**Duality of Interest**

No potential conflicts of interest relevant to this article were reported.

**References**

1. Moran LJ, Hutchison SK, Norman RJ, Teed HJ. Lifestyle changes in women with polycystic ovary syndrome (review). Cochrane Database Syst Rev 2011, CD007506


5. Himle MJ, Thatcher SS. Depression and body image among women with polycystic ovary syndrome. J Health Psychol 2006;11:616–625

6. Dokras A. Mood and anxiety disorders in women with PCOS. Steroids 2012;77:338–341


32. Thomson RL, Spedding S, Buckley JD. Vitamin D in the aetiology and management of polycystic ovary syndrome. Clin Endocrinol 012;77:343–350


37. Costello MF, Ledger WL. Evidence-based lifestyle and pharmacological management of infertility in women with polycystic ovary syndrome. Women’s Health 2012;8:277–290